Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Fujimoto’s Thaled Now in Line for Approval for POEMS Syndrome
Fujimoto Pharmaceutical’s Thaled (thalidomide) cleared a key health ministry advisory panel on January 27 for its label expansion into POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome, putting itself in line for approval as early as next month. The…
To read the full story
Related Article
- MHLW Approves Add’l Use for Thaled, Bavencio and More
February 25, 2021
REGULATORY
- Japan Sees Limited Impact from Planned US Tariffs on Generics
July 23, 2026
- MHLW Vaccine Panel Advances Mumps, RSV, HPV Discussions
July 23, 2026
- Japan Moves to Bar Duplicate IRB Reviews under Single-IRB Framework
July 23, 2026
- Chuikyo OKs NHI Listing for Cuorips’ iPSC-Based Riheart
July 23, 2026
- Ishin Lawmaker Seeks Full Chuikyo Seat for Industry, but with Fiscal Responsibility
July 22, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…